EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Egetis Therapeutics AB (publ) (EGTX) fair value: what the stock is really worth

We calculate from audited financials what Egetis Therapeutics AB (publ) is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jul 16, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE · ISIN SE0003815604

ET Thin data Jul 16, 2026

Egetis Therapeutics AB (publ)

EGTX · ST

Weakest SetupStrongly overvalued and low quality.

!Fair value kr 4.00 · Strongly overvalued (−48%)
!Quality 32/100
!Mixed Growth (revenue 5y +8.9 %/yr)
!Low debt · negative free cash flow
!Trails peers (2/8)
!Narrow moat 13/100
!Evidence only low, so the estimate is less certain
!Weak on future: 28 out of 100
Watch Egetis Therapeutics AB (publ) for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 9.18 kr 3.01 Fair Value kr 4.00 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.

How to read this chart

60‑month range kr 3.01 – kr 9.18 · fair‑value band kr 2.94 – kr 5.96 · the kr 7.71 price screens above the kr 4.00 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.

Follow Egetis Therapeutics AB (publ) in your weekly email

Every Wednesday you see whether Egetis Therapeutics AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.

Show more

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.

Stock analysis

Egetis Therapeutics AB (publ) (EGTX) currently trades at kr 7.71, while our model-based Fair Value estimate is kr 4.00, implying the stock looks roughly 92.6% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: kr 2.94 (bear) to kr 5.96 (bull), the price of kr 7.71 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Egetis Therapeutics AB (publ) reported revenue of 62.4M SEK in FY2025 versus 38.2M SEK in FY2021, a compound +13.0%/yr. Reported net income was −343M SEK in FY2025.

Key figures

Market cap 2.8B SEK (≈ $286M) · P/S ratio 46.4 · EPS (TTM) kr −0.9000 · Return on equity −110% · Return on assets (EBIT) −38.5% · Operating margin −693% · Revenue (TTM) 63.1M SEK · Revenue growth (YoY) +5.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The share trades about 4% below its 52-week high and 79% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −48%, EGTX screens richer than that median.

Fair Value models

Bear kr 2.94 Fair Value kr 4.00 Bull kr 5.96
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 0.3600 kr 0.4900 kr 0.7300 54
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.3600 kr 0.4900 kr 0.7300 54

Open the full fair value analysis →

Notify me when EGTX reaches fair value

Put EGTX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 32/100

Of which business quality 33 · Market factors (momentum, volatility) 73

Profitability 1
Margins and returns on capital today
Quality Growth 54
Are margins and returns improving?
Cashflow 6
Earnings quality: real cash, not paper profit
Fin. Strength 67
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 44
Calm price path (market factor)
Momentum 87
Price trend over the last 3–12 months (market factor)
52W Momentum 82
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+35.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
Start year 2020 (pandemic)
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+95.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−438.7% (2020) → −555.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

EGTX screens 93% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Egetis Therapeutics AB (publ) with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −48% · Below median
Profitability
Return on assets −35% · Bottom 25%
Growth and dividend
Revenue growth 6% · Above median
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.84× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 4.53× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)28 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)93 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Egetis Therapeutics AB (publ) · Fair Value
kr 4.00 −93%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Egetis Therapeutics AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/EGTX

Frequently asked questions

Is Egetis Therapeutics AB (publ) (EGTX) overvalued or undervalued?
As of Jul 16, 2026, our model estimates a fair value of kr 4.00 versus a price of kr 7.71, about −48% upside (overvalued).
What is the fair value of EGTX?
Our model-based fair value for Egetis Therapeutics AB (publ) is kr 4.00 (as of Jul 16, 2026), built from audited fundamentals. The current price: kr 7.71.
What is the quality score of EGTX?
Egetis Therapeutics AB (publ) has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Egetis Therapeutics AB (publ) (EGTX)?
Our model-based price target is the fair value of kr 4.00 (as of Jul 16, 2026) from 1 valuation models. Cautious scenario kr 2.94, optimistic scenario kr 5.96. It is a calculation from audited fundamentals, not an analyst target.
What is the Egetis Therapeutics AB (publ) stock forecast for 2026?
Our models put fair value at kr 4.00, about −48% upside versus a price of kr 7.71 (overvalued). Cautious scenario kr 2.94, optimistic scenario kr 5.96. The calculation is refreshed regularly with new filings.
What is the revenue of Egetis Therapeutics AB (publ) (EGTX)?
Egetis Therapeutics AB (publ) reported trailing-twelve-month revenue of about 63.1M SEK (latest available figure, as of Jul 16, 2026).
What is the intrinsic value of Egetis Therapeutics AB (publ) (EGTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Egetis Therapeutics AB (publ) it is kr 4.00 per share (as of Jul 16, 2026), against a price of kr 7.71. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Egetis Therapeutics AB (publ) stock overvalued or undervalued in 2026?
As of Jul 16, 2026, EGTX trades above its calculated fair value: price kr 7.71, fair value kr 4.00, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EGTX?
No. The price is what the market pays today (kr 7.71); the fair value is what the company's own numbers justify (kr 4.00). For Egetis Therapeutics AB (publ) the two are kr 3.71 per share apart. That gap is exactly why we show both numbers side by side.
How much is Egetis Therapeutics AB (publ) worth?
The market values Egetis Therapeutics AB (publ) at about 2.8B SEK (market capitalisation, as of Jul 16, 2026). Per share that is kr 7.71; our models calculate a fair value of kr 4.00 per share.
What do the bullish and bearish scenarios say about EGTX?
Our models span a range for Egetis Therapeutics AB (publ): cautious scenario kr 2.94, base kr 4.00, optimistic kr 5.96 per share (as of Jul 16, 2026, price kr 7.71). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Egetis Therapeutics AB (publ) (EGTX)?
Balance-sheet figures for Egetis Therapeutics AB (publ) (as of Jul 16, 2026): return on equity −109.7%, debt of 0.13 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is EGTX from its 52-week high?
Egetis Therapeutics AB (publ) trades at kr 7.71, about 4% below its 52-week high of kr 8.06 and 79% above the low of kr 4.32 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 4.00 is for.
Which stocks are comparable to Egetis Therapeutics AB (publ)?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Egetis Therapeutics AB (publ) stock attractive at the current price?
The data as of Jul 16, 2026: price kr 7.71, calculated fair value kr 4.00 (−48%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EGTX calculated?
We run Egetis Therapeutics AB (publ) through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 4.00, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Egetis Therapeutics AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Egetis Therapeutics AB (publ) (EGTX)?
The closing price on Sep 24, 2026 was kr 7.71. Our model-based fair value is kr 4.00, about −48% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Egetis Therapeutics AB (publ) right now?
The price sits above even our optimistic bull case (kr 5.96). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 2.94 to kr 5.96) leaves room in how you read the outcome.

Key figures of Egetis Therapeutics AB (publ)

How large is the market capitalisation of Egetis Therapeutics AB (publ) (EGTX)?
The market capitalisation of Egetis Therapeutics AB (publ) is 2.8B SEK (≈ $286M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Egetis Therapeutics AB (publ) (EGTX)?
The price-to-sales ratio of Egetis Therapeutics AB (publ) is 46.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Egetis Therapeutics AB (publ) (EGTX)?
Earnings per share at Egetis Therapeutics AB (publ) are kr −0.9000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Egetis Therapeutics AB (publ) (EGTX)?
The return on equity (ROE) of Egetis Therapeutics AB (publ) is −110% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Egetis Therapeutics AB (publ) (EGTX)?
On an EBIT basis the return on assets of Egetis Therapeutics AB (publ) is −38.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Egetis Therapeutics AB (publ) (EGTX)?
The operating margin of Egetis Therapeutics AB (publ) is −693% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Egetis Therapeutics AB (publ) (EGTX)?
Revenue at Egetis Therapeutics AB (publ) is growing +5.5% versus a year earlier (3y avg +40.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Egetis Therapeutics AB (publ) (EGTX) generate?
The free cash flow of Egetis Therapeutics AB (publ) is −269M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Egetis Therapeutics AB (publ) (EGTX) hold?
Egetis Therapeutics AB (publ) holds more cash than debt, 139M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Egetis Therapeutics AB (publ) in the live analysis

One click puts Egetis Therapeutics AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.